Close Menu

Biotia: Barry Zeman, Don Goldmann, Steven Salzberg

Dec 10, 2019

Biotia has added Barry Zeman, Don Goldmann, and Steven Salzberg to its scientific and clinical advisory board. Zeman is chief strategy officer and vice chairman of inpatient psychiatric hospital organization Assurance Health System, as well as chief stategy officer of telehealth company MedSign. Goldmann is an epidemiologist at the Harvard T.H. Chan School of Public Health and CSO emeritus for the Institute for Healthcare Improvement, a Boston-based patient safety organization. Salzberg is director of the Center for Computational Biology in the McKusick-Nathans Institute of Genetic Medicine at Johns Hopkins University.

More Like This

Mar 04, 2021

Precipio: Ron Andrews

Precipio has announced that Ron Andrews has joined the company's Board of Directors. In addition to currently serving as CEO of molecular diagnostics firm OncoCyte, Andrews' past experiences include a term as CEO of Roche Molecular, president of the genetic science division at Thermo Fisher Scientific, president of the medical sciences venture at Life Technologies, and CEO of Clarient.

Mar 03, 2021

Omniome: Thomas O'Lenic

Sequencing firm Omniome has appointed Thomas O'Lenic as chief commercial officer. O'Lenic previously held commercial, general manager, and executive leadership positions with Advanced Cell Diagnostics (now part of Bio-Techne); IntegenX (now part of Thermo Fisher Scientific); Molecular Devices (a Danaher company); PerSeptive Biosystems, Millipore, and FreeSlate.

Mar 03, 2021

Geneoscopy: Vince Wong

Geneoscopy has appointed Vince Wong as it Chief Commercial Officer. Wong previously served as VP of sales at Roche Diagnostics. He has also served as VP and general manager of physician office and specialty diagnostics at the firm. 

Mar 03, 2021

Transplant Genomics: Nicholas Grund, John Slaught, Charles Argentine

Transplant Genomics has appointed Nicholas Grund as President, John Slaught as vice president of sales, and Charles Argentine as director of clinical operations.

Grund will be responsible for developing and implementing new strategies to grow Transplant Genomics' existing business, expanding the company's TruGraf portfolio into new organ types, and working with customers, advocates, and payors to establish long term relationships. He will head company initiatives to increase TruGraf usage in the community-based nephrology market, and will also shepherd the launch of TruGraf Liver in the second half of 2021.

Grund has more than 25 years of commercial leadership experience in the biopharmaceutical industry, including several global executive roles in finance, sales, and marketing. He previously served as chief commercial officer at AMAG Pharmaceuticals, and also spent 13 years at Sanofi, most recently as the leader of the company's rare disease and multiple sclerosis franchises in the Asia Pacific region and Canada. 

Slaught has more than 25 years of commercial team leadership. He most recently served as VP of sales for Optum.

Argentine has more than 15 years of laboratory management experience, primarily in the areas of genetic sequencing and immunology. He most recently served as director of clinical laboratory operations at Roche Sequencing Solutions.

Mar 03, 2021

Arbor Biotechnologies: Mark Angelino

Arbor Biotechnologies has appointed Mark Angelino to its board of directors. 

Angelino has more than 20 years of expertise in working with numerous pharmaceutical companies, Arbor said. He was the cofounder and chief operating officer of Generation Bio from 2016 until 2021, and has also served as as senior vice president of pharmaceutical sciences and the rare disease franchise head at bluebird bio from 2012 until 2016. He also served as senior director of R&D and site head in Cambridge, Massachusetts for Baxter Healthcare from 2010 to 2012. 

Mar 03, 2021

Seven Bridges: David Ledbetter, Neil Martin, Chris Mattman

Seven Bridges has created a strategic advisory board and named three members. David Ledbetter, chief clinical officer at Dascena, is a former executive VP and chief scientific officer at Geisinger Health System and a longtime professor of human genetics. Neurosurgeon Neil Martin is director of quality and innovation at Pacific Neuroscience Institute Foundation and previously ran the neuroscience institute at Geisinger. Chris Mattman is division manager of the AI, Analytics, and Innovative Development Organization in the IT section of NASA's Jet Propulsion Laboratory, and also is director of the information retrieval and data science group at the University of Southern California.

Mar 01, 2021

GA4GH: Susan Fairley

The Global Alliance for Genomics and Health (GA4GH) has named Susan Fairley the group's first-ever chief standards officer. As such, Fairley will oversee standards development work by GA4GH's technical staff and by more than 200 external contributors. Fairley, who will be based at the European Molecular Biology Laboratory's European Bioinformatics Institute in Cambridge, UK, formerly was project lead for EMBL-EBI's International Genome Sample Resource.

Mar 01, 2021

ERS Genomics: Jon Kratochvil

ERS Genomics has appointed Jon Kratochvil as vice president for business development and licensing for North America. Kratochvil previously served as director of business development and licensing at MilliporeSigma, where he was responsible for global development opportunities for the company's gene editing and novel modalities technologies. He has also previously served as business development director for Washington University, and as licensing manager and competitive intelligence analyst for Abbott Laboratories' diagnostics division.

Feb 24, 2021

Ultivue: Mike Sismour, Mark Rees

Ultivue, a company specializing in multiplex biomarker assays for tissue phenotyping and digital pathology, has appointed Mike Sismour as vice president, research, and Mark Rees as vice president, corporate development.

Sismour most recently served as chief scientist/head of genomics R&D at Beckman Coulter Life Science. He was a National Institutes of Health Ruth L. Kirschstein postdoc at Harvard Medical School and a fellow at Harvard's Wyss Institute.

Rees most recently worked for StatLab where he helped create a diagnostic division. He previously held leadership roles in commercial development, scientific affairs, and R&D at Enzo Life Sciences, Leica Biosystems (Danaher), and Novocastra Laboratories.

Feb 23, 2021

908 Devices: Jeff George, Fenel Eloi

Mass spectrometry firm 908 Devices has appointed Jeff George and Fenel Eloi to its board of directors.

George has previously served as the global division head and CEO of two divisions of Novartis, Sandoz, and Alcon from 2008 to 2016. In parallel, he served on the Novartis Group executive committee. He also serves on the board of directors of Amneal Pharmaceutical, Dorian Therapeutics, and Wishbone Medical.

Eloi previously served as CFO then COO at Cell Signaling Technology. He also serves on the board of directors of MitoTherapeutix.

Feb 23, 2021

ImmunoScape: Geoff Nosrati

Singapore-based immune profiling company ImmunoScape has named Geoff Nosrati as chief business officer in conjunction with the establishment of the firm's US headquarters in San Diego. Before joining ImmunoScape, Nosrati advised biotechnology clients at McKinsey & Co. He also held senior executive positions at Aduro Biotech. Nosrati holds a PhD in biochemistry and molecular biology from the University of California, Los Angeles.

Feb 23, 2021

Qiagen: Thomas Ebeling

Thoms Ebeling has been appointed to Qiagen's supervisory board. Ebeling has been an advisor in recent years to various companies after having served as CEO of German media group ProSiebenSat.1 from 2009 to 2018. Prior to that he worked for Novartis from 1997 to 2008, including as CEO of Novartis Pharmaceuticals and CEO of Novartis Consumer Health. Ebeling has also previously served on the supervisory boards of Bayer and Lonza.

Feb 19, 2021

Siemens Healthineers, Centogene: Peer Schatz

Peer Schatz was elected to the supervisory board of Siemens Healthineers on Feb. 12 at the company's annual shareholders' meeting. The company proposed his addition to the board on Jan. 5.

In addition, Schatz has become chairman of the supervisory board of Centogene, effective Jan. 1, 2021, after having joined the board last summer. He replaced Flemming Ornskov, who was chairman from April 1, 2019 until Dec. 31, 2020.

Schatz is the former CEO of Qiagen, a position he held from 1993 until 2019. He is currently managing director of PS Capital Management and is chairman of the board and cofounder of spatial genomics startup Resolve Biosciences. Before Qiagen, he had various roles at ComputerLand and at Sandoz and cofounded several startup companies in the IT industry. Schatz holds an master's degree in finance from the University of St. Gallen and an MBA from the University of Chicago Graduate School of Business.

Feb 19, 2021

Myriad Genetics: Kevin Haas, Faith Zaslavsky

Myriad Genetics has promoted Kevin Haas and Faith Zaslavsky. Haas, will be Myriad's new chief technology officer and report to CEO Paul Diaz. He has held various senior level positions in R&D, bioinformatics, engineering, and technology since joining the company in 2013. Zaslavsky will be president of the Myriad Oncology business unit, which she has been general manager of since 2019.

Feb 18, 2021

Infinity BiologiX: Shareef Nahas, Sameer Kalghatgi

Infinify BiologiX (IBX) has named Shareef Nahas as vice president of global laboratory operations and clinical services and interim CSO, and Sameer Kalghatgi as senior director of laboratory operations.

Nahas will report to Robin Grimwood, president and interim CEO of IBX. Nahas and Grimwood assume their interim roles following the recent passing of Andrew Brooks. Nahas was previously senior director of operations at Rady Children's Institute of Genomic Medicine in San Diego. Prior to that he held a number of senior laboratory roles at Genoptix (Novartis) and Ambry Genetics. He received his PhD in molecular toxicology from the University of California, Los Angeles.

Kalghatgi joins IBX from Coriell Institute for Medical Research, where he served as director of laboratory operations. He will report to Nahas at IBX.

IBX previously operated as RUCDR Infinite Biologics before spinning off from Rutgers University-New Brunswick in August 2020. Its COVID-19 saliva test was the first to receive US Food and Drug Administration Emergency Use Authorization. The company primarily provides sample collection, processing, storage, and analytical services to research and clinical customers.

European regulators have begun a rolling review of Russia's Sputnik V SARS-CoV-2 vaccine, Reuters reports.

Science reports that Science Foundation Ireland is seeking annual budget increases.

According to the Financial Times, a UK university group is pushing Elsevier to lower its journal fees.

In Nature this week: satellite tracking and genome sequencing combination used to examine migration patterns of peregrine falcons, and more.